Navigation Links
BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
Date:3/30/2008

With high-dose clopidogrel, the intravenous anti-platelet drug appears

unnecessary

CHICAGO, March 30 /PRNewswire/ -- Over the years, interventional cardiologists have made many improvements in percutaneous coronary intervention (PCI) for patients with heart attack, among the most important, refinements in the selection and administration of drugs that prevent unwanted blood clotting. Now a new study has found that high loading doses of clopidogrel, an oral medication that inhibits blood clots by preventing platelets from clumping together, can eliminate the need for intravenous abciximab, a standard cath-lab drug that also interferes with platelets, but through a different pathway.

The BRAVE-3 study is the first to test the influence of high-dose clopidogrel on the value of abciximab exclusively in patients with ST-elevation myocardial infarction (STEMI), a serious form of heart attack. The study is being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

"Acute myocardial infarction is a major medical problem, and the present study will help to define the optimal treatment strategy," said Julinda Mehilli, MD, an associate professor and staff cardiologist at Deutsches Herzzentrum, Technical University, Munich, Germany. "Therapy without abciximab would certainly be more cost-effective and reduce the risk of bleeding complications."

For the study Dr. Mehilli and colleagues recruited 800 patients with STEMI who were undergoing PCI. All patients were pretreated with 600 mg of clopidogrel and then randomly assigned to receive intravenous abciximab or a placebo during the procedure.

The study was designed primarily to compare how the two treatment strategies affected the final amount of heart attack damage, as gauged by blood flow in the heart muscle on a nuclear scan five to 10 days later. The researchers found no difference between the two groups: The damage involved 10 percent of the left ventricle, on average, in the abciximab group and 9 percent of the left ventricle in the placebo group. In addition, the 30-day combined rates of death, heart attack, stroke and urgent repeat coronary procedures were similar in the two groups (5 percent and 3.8 percent, respectively).

"For patients with acute ST-elevation myocardial infarction undergoing primary coronary intervention after pre-treatment with a 600-mg loading dose of clopidogrel, the additional use of abciximab is not associated with any measurable benefit after 30 days," Dr. Mehilli said.

Dr. Mehilli will present the results of the BRAVE-3 study on Sunday, March 30 at 8:30 a.m. CDT in the Grand Ballroom, S100.

About SCAI

Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in over 60 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty.

About ACC

The American College of Cardiology is leading the way to optimal cardiovascular care and disease prevention. The College is a 34,000-member nonprofit medical society and bestows the credential Fellow of the American College of Cardiology upon physicians who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care.


'/>"/>
SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Replikins LLC Finds West Nile Virus Replikin Count Has Reached Its Highest Recorded Value
2. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
3. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
4. Industry Executives Finding Value in Shift of Scientific Publications
5. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
6. Many Heart Attack Patients Dont Get Best Emergency Treatment
7. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
8. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
9. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
10. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
11. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... -- E.I. Medical Imaging (EIMI) has partnered with Dr. ... the worlds first ultrasound system to be used underwater to ... In preparation for a piece produced by Icon films ... Guttridge approached EIMI with the idea of an underwater ultrasound ... underwater. EIMI produces ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... Massachusetts , July 25, 2017 The med-tech ... rare nervous system diseases, has concluded a worldwide license agreement ... drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement ... a Phase 2 study conducted in Europe ... the United States ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... 17, 2017 , ... Finalists in the 2017 (second annual) ... The awards recognize the world’s best employers and the human resources professionals, teams, ... places to work. , A diverse group of organizations and individuals around the ...
(Date:8/16/2017)... Chicago, IL (PRWEB) , ... August 16, 2017 , ... ... leadership team as Senior Vice President, Chief Medical Officer. Dr. Spiro brings over 30 ... he will provide strategic leadership for BHI’s cutting-edge analytics solutions. , “I am ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... their recently launched community enrichment program. Partnering once again with Boys & Girls ... competition to help find the area’s very own American Idol. With all proceeds ...
(Date:8/16/2017)... Cumberland, PA (PRWEB) , ... August 16, 2017 , ... ... today it has successfully opened clubfoot clinics in all 29 Indian states—bringing the country ... newest clinic in Kangra, Himachal Pradesh, the nonprofit organization is on track to enroll ...
Breaking Medicine News(10 mins):